(Geron) LOS ANGELES (BP) -- In a surprising move, the company that launched the nation's first government-approved embryonic stem cell trial is halting further research due to funding -- a shift that pro-life leaders say confirms long-held doubts about the value of embryonic stem cells.
Geron, which launched the first FDA-approved embryonic stem cell trial in 2010 with much fanfare, said Nov. 14 it will stop funding its stem cell trials and move that money to cancer research, a move it said is necessary in the "current environment of capital scarcity and uncertain economic conditions."
The shift is effective immediately. MORE
No comments:
Post a Comment